Abbott Laboratories (ABT) Long-Term Debt Issuances (2010 - 2026)

Abbott Laboratories has disclosed Long-Term Debt Issuances across 10 years of filings, most recently posting $19.9 billion for Q1 2026.

• Long-Term Debt Issuances for Q1 2026 came in at $19.9 billion, up 1985900.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.9 billion (up 8767.86% YoY), and the FY2025 annual result was $5.0 million, down 97.76% from the prior year.
• Long-Term Debt Issuances came in at $19.9 billion for Q1 2026 at Abbott Laboratories, up from $2.0 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $19.9 billion in Q1 2026 to a low of $1.0 million in Q3 2022.
• The 5-year median for Long-Term Debt Issuances is $1.0 million (2022), against an average of $2.2 billion.
• Across the five-year window, Long-Term Debt Issuances sank 99.1% in 2025 and surged 1985900.0% in 2026, its largest moves.
• Abbott Laboratories' Long-Term Debt Issuances stood at $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024, then soared by 100.0% to $2.0 million in 2025, then soared by 992900.0% to $19.9 billion in 2026.
• The last three Long-Term Debt Issuances figures came in at $19.9 billion (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q2 2025), per Business Quant data.